medigraphic.com
ISSN 1561-302X (Print)

2021, Number 2

<< Back Next >>

Rev cubana med 2021; 60 (2)

The cardiovascular system and damage induced by coronavirus-2 infection

Elias AKS, Pérez MK, Batista CM

Language: Spanish
References: 42
Page: 1-9
PDF size: 291.72 Kb.


ABSTRACT

Introduction: There are questions around the cardiovascular damage caused by coranavirus-2 (SARS-CoV-2) infection, which causes the disease known as COVID-19, which motivates interest in the subject.
Objective: To describe the cardiovascular manifestations in COVID-19 disease.
Method: A narrative bibliographic review was carried out through the documentary study of systematic reviews and original articles related to the cardiovascular manifestations of COVID-19, from May to September 2020, at the University of Medical Sciences in Guantánamo. The search was carried out in the bibliographic databases Pubmed, Infomed, Medline, Science Direct, and SciELO. Google Academic search engine was used, and the keywords and connectors were COVID-19 AND cardiovascular disease; SARS-CoV-2 AND cardiovascular disease, and the terms in Spanish. Data extraction was carried out according to a template that summarized the questions of interest according to the objective of this review.
Findings: It is recognized that the systemic inflammatory response triggered by SARS-CoV-2 can damage the myocardium. Cardiovascular manifestations are frequent and varied, the most common are myocarditis, heart failure, cardiac arrhythmias, and acute coronary syndrome. Those individuals with cardiovascular disease are at risk of decompensation, increased risk of myocardial damage from this infection, and increased morbidity and mortality.
Conclusion: The COVID-19 pandemic determines cardiovascular damage that is expressed by the presentation of myocarditis, heart failure, cardiac arrhythmias, acute coronary syndrome, pericardial effusion and cardiac tamponade; most common manifestations in patients with a history of cardiovascular disease, which conditions unfavorable prognosis.


REFERENCES

  1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. 2020[acceso: 13/09/2020]. Disponible en: Disponible en: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020

  2. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report, 101. 2020[acceso: 13/09/2020]. Disponible en: Disponible en: https://apps.who.int/iris/hanjdle/10665/332054

  3. Cuba, Ministerio de Salud Pública. Parte de cierre del día 12 de septiembre de 2020 a las 12 de la noche. 2020[acceso: 13/09/2020]. Disponible en: Disponible en: https://salud.msp.gob.cu/?p=5681

  4. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable origin. Nature. 2020;579(7798):270-73. Disponible en: https://doi.org/10.1038/s41586-020-2012-7

  5. Palacios CM, Santos E, Velázquez CMA, León JM. COVID-19 una emergencia de salud pública mundial. Rev Clin Esp. 2020;1885. Disponible en: https://doi.org/10.1016/j.rce.2020.03.001

  6. Wu P, Hao X, Lau EHY, Wong JY, Leung KSM, Wu JT, et al. Real time tentative assesment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January, 2020. Euro Surveill. 2020;25(3):pii2000044. Disponible en: https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000044

  7. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(2019):727-33. Disponible en: https://doi.org/doi:10.1056/NEJMoa2001017

  8. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450-55. Disponible en: https://doi.org/10.1038/s41591-020-0820-9

  9. Rothan HA, Siddappa NB. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020;109. Disponible en: https://doi.org/10.1016/j.jaut.2020.102433

  10. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus disease 2019 (COVID-19) cardiovascular disease. Circulation. 2020[acceso: 13/09/2020];141:1648-55. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32200663/

  11. Deepak A, Siddiqi HK, Lang JP, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the Cardiologist. Basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies. JACC: basic to translational science. 2020;5(5):518-36. Disponible en: https://doi.org/10.1016/j.jacbts.2020.04.002

  12. Matsushita K, Marchandot B, Jesel L, Ohlmann P, Morel O. Impact of COVID-19 on the Cardiovascular System: A Review. J. Clin. Med. 2020. Disponible en: http://doi.org/doi:10.3390/jcm9051407

  13. Naranjo DA, Valdés MA. COVID-19. Punto de vista del cardiólogo. Rev Cub Cardio Cir Cardiov. 2020[acceso: 13/09/2020]26(1):1-5. Disponible en: Disponible en: http://www.revcardiologia.sld.cu/index.php/revcardiologia/article/view/951/pdf

  14. Moreno MFL, Moreno LFL, Oroz MR. Repercusión cardiovascular de la infección por el nuevo coronavirus SARS-CoV-2 (COVID-19). CorSalud. 2020[acceso: 13/09/2020];12(1):3-17. Disponible en: Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/downloadview/588/1112

  15. Madjid M, Safavi NP, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020[acceso: 13/09/2020]. Disponible en: Disponible en: https://jamanetwork.com/journals/jamacardiology/fullarticle/2763846

  16. Kobayashi T, Jung SM, Linton NM, Kinoshita R, Hayashi K, Miyama T, et al. Communicating the risk of death from novel coronavirus disease (COVID-19). J Clin Med. 2020[acceso: 13/09/2020];9(2):580. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073841/pdf/jcm-09-00580.pdf

  17. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798-1800. Disponible en: https://doi.org/10.1093/eurheartj/ehaa231

  18. Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol . 2020. Published online 27, March 2020. Disponible en: http://doi.org/10.1001/jamacardio.2020.1105

  19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 2019 Lancet. 2020[acceso: 13/09/2020];395(10223):497-506. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(20)30183-5

  20. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-48. Disponible en: https://doi.org/10.1007/s00134-020-05991-x

  21. Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute syndrome coronavirus 2 infection. JAHA. 2020;9(7):e016219. Disponible en: https://doi.or/10.1161/JAHA.120.016219

  22. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60. Disponible en: http://doi.org/10.1038/s41569-020-0360-5

  23. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J. 2020. Published online 16, March 2020. Disponible en: https://doi.org/10.1093/eurheartj/ehaa190

  24. García SA. Revisión narrativa sobre la respuesta inmunitaria frente a coronavirus: descripción general, aplicabilidad para SARS-COV-2 e implicaciones terapéuticas. An Pediatr (Barc). 2020. Disponible en: https://doi.org/10.1016/j.anpedi.2020.04.016

  25. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin- converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Inten- sive Care Med. 2020[acceso: 13/09/2020];46:586-90. Disponible en: Disponible en: http://refhub.elsevier.com/S0120-5633(20)30091-7/sbref0150

  26. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol. 2020. Disponible en: http://dx.doi.org/.1016/j. jacc.2020.03.031

  27. Noria S, Bachini JP, Ramos MV. Coronavirus y sistema cardiovascular. Rev. Urug. Cardiol. 2020[acceso: 13/09/2020];35(2):420-22. Disponible en: Disponible en: http://www.scielo.edu.uy/pdf/ruc/v35n2/1688-0420-ruc-35-02-193.pdf

  28. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl J Med. 2020;382:1708-20. Disponible en: http://dx.doi.org/10.1056/NEJMoa2002032

  29. Madjid M, Safavi NP, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol . 2020. Disponible en: https://doi.org/10.1001/jamacardio.2020.1286

  30. Hendren NS, Drazner MH, Bozkurt B, Cooper LT. Description and proposed management of the acute COVID-19 Cardiovascular Syndrome. Circulation. 2020[acceso: 13/09/2020];7(1):11-12. Disponible en: Disponible en: http://refhub.elsevier.com/S0120-5633(20)30091-7/sbref0135

  31. Nunes KA, Tagliari AP, Battista FG, Michele FG, Tondo C. Cardiac and arrhythmic complications in patients with COVID‐19. J Cardiov Electrophysiology. 2020;31(5):1003-08. Disponible en: https://doi.org/10.1111/jce.14479

  32. Donner B, Niranjan V, Hoffmann G. Safety of oseltamivir in pregnancy: a review of preclinical and clinical data. Drug Saf. 2020;33(8):631-42. Disponible en: https://dx.doi.org/10.2165/11536370-000000000-00000

  33. Rao S, Sasser W, Díaz F, Sharma N, Alten J. Coronavirus associated fulminant myocarditis successfully treated with intravenous inmunoglobulin and extracorporeal membrane oxygenation Chest. 2020[acceso: 13/09/2020];146(4):336A. Disponible en: Disponible en: https://europepmc.org/abstract/med/25334353

  34. García FMA, Gómez de Diego JJ. COVID-19 y afectación cardíaca. Rev Chil Anest. 2020;49:397-400. Disponible en: https://doi.org/10.25237/revchilanestv49n03.018

  35. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-69. Disponible en: https://doi.org/10.1001/jama.2020.1585

  36. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet . 2020[acceso: 13/09/2020];395:1054-62. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/32171076/

  37. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. Disponible en: https://doi.org/10.1016/S2213-2600(20)30079-5

  38. García HAR, Rivero SSL, Aroche AR, Aldama PLI, Hernández NM. COVID-19: en torno al sistema cardiovascular. Rev Anales Academia Ciencias Cuba. 2020[acceso: 13/09/2020];10(2) especial COVID-19. Disponible en: Disponible en: http://www.revistaccuba.sld.cu/index.php/revacc/article/view/782/821

  39. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med . 2020;382(17):e38. Disponible en: https://doi.org/10.1056/nejmc2007575

  40. Gauna ME, Bernava JL. Recomendaciones diagnósticas y terapéuticas ante la Respuesta Inmune Trombótica Asociada a Covid-19 (RITAC). CorSalud. 2020[acceso: 13/09/2020];12(1):60-3. Disponible en: Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/615/1110

  41. López PJJD, Ponce de León PA, Cárdenas MPA, Giraldo GGC, Herrera EA. Coronavirus-COVID 19: Más allá de la enfermedad pulmonar, qué es y qué sabemos del vínculo con el sistema cardiovascular. Rev Colomb Cardiol. 2020[acceso: 13/09/2020];S0120-5633(20)30078-4. Disponible en: Disponible en: https://doi.org/doi:10.1016/j.rccar.2020.04.006

  42. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 2020;7(1):11-12. Disponible en: https://doi.org/10.1186/s40779-020-00240-0




2020     |     www.medigraphic.com